Genomics	B:C0887950
of	O
Myeloproliferative	O
Neoplasms	I:C0027022
.	O

Genomics	O
of	O
Myeloproliferative	B:C0027022
Neoplasms	I:C0027022
.	O

Myeloproliferative	B:C0027022
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	B:C0027022
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	B:C1522642
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	B:C0018939
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	B:C4055506
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	B:C0887899
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Myeloproliferative	O
neoplasms	I:C0027022
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	I:C0018939
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	I:C0887899
lineages	I:C0887899
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	B:C0023467
myeloid	I:C0023467
leukemia	I:C0023467
.	O

Deregulated	O
JAK2	B:C1334291
signaling	O
has	O
emerged	O
as	O
the	O
central	O
phenotypic	O
driver	O
of	O
BCR	O
-	I:C1292772
ABL1	I:C1292772
-	I:C1292772
negative	I:C1292772
MPNs	I:C1292772
and	O
a	O
unifying	O
therapeutic	O
target	O
.	O

Deregulated	O
JAK2	O
signaling	B:C3537152
has	O
emerged	O
as	O
the	O
central	O
phenotypic	O
driver	O
of	O
BCR	O
-	I:C1292772
ABL1	I:C1292772
-	I:C1292772
negative	I:C1292772
MPNs	I:C1292772
and	O
a	O
unifying	O
therapeutic	O
target	O
.	O

Deregulated	O
JAK2	O
signaling	O
has	O
emerged	O
as	O
the	O
central	O
phenotypic	O
driver	O
of	O
BCR	B:C1292772
-	I:C1292772
ABL1	I:C1292772
-	I:C1292772
negative	I:C1292772
MPNs	I:C1292772
and	O
a	O
unifying	O
therapeutic	O
target	O
.	O

In	O
addition	O
,	O
MPNs	B:C0027022
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	I:C0000772
associated	O
with	O
disease	O
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	B:C0853141
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	I:C0000772
associated	O
with	O
disease	O
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	B:C0000772
abnormalities	I:C0000772
associated	O
with	O
disease	O
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	I:C0000772
associated	O
with	O
disease	B:C0242656
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	I:C0000772
associated	O
with	O
disease	O
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	B:C0026882
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	I:C0000772
associated	O
with	O
disease	O
progression	I:C0242656
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	I:C0026882
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	B:C0026882
are	O
acquired	O
.	O

Although	O
morphology	O
and	O
clinical	O
laboratory	O
analysis	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
defining	O
these	O
conditions	O
,	O
genomic	B:C0022885
analysis	I:C0022885
is	O
providing	O
a	O
platform	O
for	O
better	O
disease	O
definition	O
,	O
more	O
accurate	O
diagnosis	O
,	O
direction	O
of	O
therapy	O
,	O
and	O
refined	O
prognostication	O
.	O

Although	O
morphology	O
and	O
clinical	O
laboratory	O
analysis	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
defining	O
these	O
conditions	O
,	O
genomic	O
analysis	I:C0022885
is	O
providing	O
a	O
platform	O
for	O
better	O
disease	O
definition	O
,	O
more	O
accurate	O
diagnosis	B:C0011900
,	O
direction	O
of	O
therapy	O
,	O
and	O
refined	O
prognostication	O
.	O

Although	O
morphology	O
and	O
clinical	O
laboratory	O
analysis	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
defining	O
these	O
conditions	O
,	O
genomic	O
analysis	I:C0022885
is	O
providing	O
a	O
platform	O
for	O
better	O
disease	O
definition	O
,	O
more	O
accurate	O
diagnosis	O
,	O
direction	O
of	O
therapy	B:C0087111
,	O
and	O
refined	O
prognostication	O
.	O

Although	O
morphology	O
and	O
clinical	O
laboratory	O
analysis	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
defining	O
these	O
conditions	O
,	O
genomic	O
analysis	I:C0022885
is	O
providing	O
a	O
platform	O
for	O
better	O
disease	O
definition	O
,	O
more	O
accurate	O
diagnosis	O
,	O
direction	O
of	O
therapy	O
,	O
and	O
refined	O
prognostication	B:C0033325
.	O

There	O
is	O
an	O
emerging	O
consensus	O
with	O
regard	O
to	O
many	O
prognostic	B:C1514474
factors	I:C1514474
,	O
but	O
there	O
is	O
a	O
clear	O
need	O
to	O
synthesize	O
genomic	O
findings	O
into	O
robust	O
,	O
clinically	O
actionable	O
and	O
widely	O
accepted	O
scoring	O
systems	I:C0282574
as	O
well	O
as	O
the	O
need	O
to	O
standardize	O
the	O
laboratory	O
methodologies	I:C0449309
that	O
are	O
used	O
.	O

There	O
is	O
an	O
emerging	O
consensus	O
with	O
regard	O
to	O
many	O
prognostic	O
factors	I:C1514474
,	O
but	O
there	O
is	O
a	O
clear	O
need	O
to	O
synthesize	O
genomic	B:C0017428
findings	O
into	O
robust	O
,	O
clinically	O
actionable	O
and	O
widely	O
accepted	O
scoring	O
systems	I:C0282574
as	O
well	O
as	O
the	O
need	O
to	O
standardize	O
the	O
laboratory	O
methodologies	I:C0449309
that	O
are	O
used	O
.	O

There	O
is	O
an	O
emerging	O
consensus	O
with	O
regard	O
to	O
many	O
prognostic	O
factors	I:C1514474
,	O
but	O
there	O
is	O
a	O
clear	O
need	O
to	O
synthesize	O
genomic	O
findings	O
into	O
robust	O
,	O
clinically	O
actionable	O
and	O
widely	O
accepted	O
scoring	B:C0282574
systems	I:C0282574
as	O
well	O
as	O
the	O
need	O
to	O
standardize	O
the	O
laboratory	O
methodologies	I:C0449309
that	O
are	O
used	O
.	O

There	O
is	O
an	O
emerging	O
consensus	O
with	O
regard	O
to	O
many	O
prognostic	O
factors	I:C1514474
,	O
but	O
there	O
is	O
a	O
clear	O
need	O
to	O
synthesize	O
genomic	O
findings	O
into	O
robust	O
,	O
clinically	O
actionable	O
and	O
widely	O
accepted	O
scoring	O
systems	I:C0282574
as	O
well	O
as	O
the	O
need	O
to	O
standardize	O
the	O
laboratory	B:C0449309
methodologies	I:C0449309
that	O
are	O
used	O
.	O

